Sigma 1 receptor: A novel therapeutic target in retinal disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
&NA; Retinal degenerative diseases are major causes of untreatable blindness worldwide and efficacious treatments for these diseases are sorely needed. A novel target for treatment of retinal disease is the transmembrane protein Sigma 1 Receptor (Sig1R). This enigmatic protein is an evolutionary isolate with no known homology to any other protein. Sig1R was originally thought to be an opioid receptor. That notion has been dispelled and more recent pharmacological and molecular studies suggest that it is a pluripotent modulator with a number of biological functions, many of which are relevant to retinal disease. This review provides an overview of the discovery of Sig1R and early pharmacologic studies that led to the cloning of the Sig1R gene and eventual elucidation of its crystal structure. Studies of Sig1R in the eye were not reported until the late 1990s, but since that time there has been increasing interest in the potential role of Sig1R as a target for retinal disease. Studies have focused on elucidating the mechanism(s) of Sig1R function in retina including calcium regulation, modulation of oxidative stress, ion channel regulation and molecular chaperone activity. Mechanistic studies have been performed in isolated retinal cells, such as Müller glial cells, microglial cells, optic nerve head astrocytes and retinal ganglion cells as well as in the intact retina. Several compelling studies have provided evidence of powerful in vivo neuroprotective effects against ganglion cell loss as well as photoreceptor cell loss. Also described are studies that have examined retinal structure/function in various models of retinal disease in which Sig1R is absent and reveal that these phenotypes are accelerated compared to retinas of animals that express Sig1R. The collective evidence from analysis of studies over the past 20 years is that Sig1R plays a key role in modulating retinal cellular stress and that it holds great promise as a target in retinal neurodegenerative disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“DMT induces head twitch response in wildtype, but not 5-HT2a knockout mice and 5-HT2a is a serotonin receptor sub-type (Keiser et al., 2009).”
BackgroundYoshida, H. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05639.x · Cited by 1,086
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“NRF2 is considered a “master regulator” of the antioxidant gene response as it modulates transcription of more than 500 antioxidant and cytoprotective genes (Sporn and Liby, 2012; Gorrini et al., 2013).”
BackgroundRetinal degeneration mutants in the mouse
Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Nusinowitz, S., & Heckenlively, J. R. (2002) · Vision Research · doi:10.1016/s0042-6989(01)00146-8 · Cited by 840
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Crystal structure of the human σ1 receptor
Schmidt, H. R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., & Kruse, A. C. (2016) · Nature · doi:10.1038/nature17391 · Cited by 482 · cited 1×
“The description of the approach to determine the crystal structure of Sig1R has been published (Schmidt et al., 2016).”
BackgroundMüller Glial Cells in Retinal Disease
Bringmann, A., & Wiedemann, P. (2012) · Ophthalmologica · doi:10.1159/000328979 · Cited by 436
Tan, E., Ding, X.-Q., Saadi, A., Agarwal, N., Naash, M. I., & Al-Ubaidi, M. R. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1114 · Cited by 345 · cited 1×
“line (661W) developed by the Al-Ubaidi group (Tan et al., 2004).”
Background
Cited by
The Molecular Function of σ Receptors: Past, Present, and Future
Schmidt, H. R., & Kruse, A. C. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.006 · Cited by 177
σ2R/TMEM97 in retinal ganglion cell degeneration
Wang, H., Peng, Z., Li, Y., Sahn, J. J., Hodges, T. R., Chou, T.-H., Liu, Q., Zhou, X., Jiao, S., Porciatti, V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24537-3 · Cited by 13
Mavlyutov, T. A., Li, J., Liu, X., Shen, H., Yang, H., McCurdy, C. R., Pattnaik, B., & Guo, L.-W. (2022) · Genes · doi:10.3390/genes13122386 · Cited by 7
Metadata
- Authors
- Smith, S. B., Wang, J., Cui, X., Mysona, B. A., Zhao, J., & Bollinger, K. E.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 67
- Pages
- 130-149
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2886919003
- Cited by
- 66
- References
- 13
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sigma 1 receptor: A novel therapeutic target in retinal disease. https://app.cochat.ai/papers/10.1016/j.preteyeres.2018.07.003
- The paper
- Smith, S. B., Wang, J., Cui, X., Mysona, B. A., Zhao, J., & Bollinger, K. E. (2018). Sigma 1 receptor: A novel therapeutic target in retinal disease. Progress in Retinal and Eye Research. https://doi.org/10.1016/j.preteyeres.2018.07.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.